Retapamulin

Drug Profile

Retapamulin

Alternative Names: '833; 275833; 275833AA; Altabax; ALTARGO; SB 275833

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antibacterials; Heterocyclic bicyclo compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gram-positive infections; Impetigo; Skin and soft tissue infections
  • Discontinued Sinusitis

Most Recent Events

  • 30 Nov 2015 Retapamulin licensed to Aqua Pharmaceuticals for commercialisation in USA
  • 23 Nov 2015 Retapamulin licensed to Almirall in USA
  • 31 May 2014 GlaxoSmithKline completes a phase I feasibility trial in Healthy volunteers in USA (NCT01812382)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top